Biomarck Pharmaceuticals to Present Expanded Analysis of BIO-11006 Clinical Data in Treatment of Non-Small Cell Lung Cancer at the American Thoracic Society 2020 International Conference
News published by Biomarck Pharmaceuticals concerning its novel anti-MARCKS peptide BIO-11006 in non-small cell lung cancer (NSCLC), administered via an optimized eFlow® Technology nebulizer.